NCT/Study#
NCT06925737 /
MK2400-001
A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Treatment of Physicians Choice in participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
DISEASE GROUP:
Genito-Urinary
current phase:
Phase III
STUDY STATUS:
Enrolling
Location:
Hackensack, NJ
For More information:
